Resultados de búsqueda - Laban Kato

  • Mostrando 1 - 1 Resultados de 1
Limitar resultados
  1. 1
    Safety and Immunogenicity of a Modified Self-Amplifying Ribonucleic Acid (saRNA) Vaccine Encoding SARS-CoV-2 Spike Glycoprotein in SARS-CoV-2 Seronegative and Seropositive Ugandan Individuals

    Safety and Immunogenicity of a Modified Self-Amplifying Ribonucleic Acid (saRNA) Vaccine Encoding SARS-CoV-2 Spike Glycoprotein in SARS-CoV-2 Seronegative and Seropositive Ugandan... por Jonathan Kitonsa, Jennifer Serwanga, Hannah M. Cheeseman, Andrew Abaasa, Jane Frances Lunkuse, Eugene Ruzagira, Laban Kato, Florence Nambaziira, Gerald Kevin Oluka, Ben Gombe, Sembera Jackson, Joseph Katende Ssebwana, Leon R. McFarlane, Sarah Joseph, Benjamin F. Pierce, Robin J. Shattock, Pontiano Kaleebu

    Publicado 2025-05-01

    Background: The COVID-19 pandemic highlighted the need for innovative vaccine platforms that elicit durable immunity. Self-amplifying RNA (saRNA) vaccines offer rapid production and dose-sparing advantages over traditional mRNA platforms. In Uganda’s first SARS-CoV-2 vaccine trial (NCT04934111), we...

    Descripción completa

    Enlace del recurso
    Artículo

    Agregar a favoritos
    Guardado en:

Herramientas de búsqueda: